Loading...

Vertex Pharmaceuticals Incorporated

VRTXNASDAQ
HealthcareBiotechnology
$441.84
$-5.25(-1.18%)

Vertex Pharmaceuticals Incorporated VRTX Peers

See (VRTX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
VRTX$441.84-1.18%113.5B-115.36-$3.83N/A
REGN$489.52-19.14%52B12.44$39.36+0.36%
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ALNY$304.56+3.98%39.7B-140.35-$2.17N/A
ARGX$573.26-1.32%35B35.00$16.38N/A
BNTX$95.81-4.43%23B-26.39-$3.63N/A
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
RPRX$32.88+0.74%18.5B13.42$2.45+2.61%
UTHR$318.85-0.47%14.4B12.71$25.09N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

VRTX vs REGN Comparison

VRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 113.5B. In comparison, REGN has a market cap of 52B. Regarding current trading prices, VRTX is priced at $441.84, while REGN trades at $489.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of -115.36, whereas REGN's P/E ratio is 12.44. In terms of profitability, VRTX's ROE is -0.06%, compared to REGN's ROE of +0.15%. Regarding short-term risk, VRTX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for VRTX.

Stock Price Comparison

Loading...

Frequently Asked Questions